Genetic Testing (PGT/PGD) in Delhi: What Every IVF Patient Needs to Know

Preimplantation Genetic Testing (PGT) and Preimplantation Genetic Diagnosis (PGD) are both techniques applied to embryos created through IVF before they are transferred to the uterus — but they serve distinct clinical purposes that Delhi patients should clearly understand.

PGT is an umbrella term covering three subtypes. PGT-A (formerly PGS) screens for aneuploidy — that is, embryos with an abnormal number of chromosomes, such as those that would result in Down syndrome or Turner syndrome. PGT-M targets specific monogenic or single-gene disorders like beta-thalassaemia, which is particularly prevalent in certain communities across North India and Delhi NCR. PGT-SR is used when one or both parents carry a chromosomal structural rearrangement such as a translocation.

PGD, in its traditional and narrower usage, refers specifically to testing embryos when parents are known carriers of a hereditary disease. For example, a couple in Rohini who are both carriers of sickle cell anaemia would use PGD to ensure only unaffected embryos are transferred. Both PGT and PGD require a trophectoderm biopsy — a safe removal of 5-8 cells from the outer layer of a Day 5 blastocyst — followed by genetic analysis using next-generation sequencing (NGS) or array comparative genomic hybridisation (aCGH). The embryo itself remains unharmed during this process.

Not every IVF cycle requires genetic testing, but for specific patient profiles, PGT or PGD can be the difference between repeated failure and a successful live birth. The HomeIVF Medical Board identifies the following as primary indications for recommending PGT or PGD in Delhi patients.

Women aged 35 and above face a statistically higher risk of chromosomally abnormal embryos due to natural egg quality decline. In this group, PGT-A helps identify the one or two euploid (chromosomally normal) embryos in a cohort, avoiding transfers that are destined to fail. Couples who have experienced two or more unexplained miscarriages — a situation we encounter frequently among patients reaching out from Lajpat Nagar and other South Delhi neighbourhoods — are strong candidates for PGT-A, as up to 60% of early pregnancy losses are caused by chromosomal aneuploidy.

Couples with a family history of hereditary conditions such as beta-thalassaemia, Duchenne muscular dystrophy, haemophilia, or spinal muscular atrophy (SMA) are advised to pursue PGT-M or PGD before embryo transfer. Men with severely poor sperm parameters, including very high DNA fragmentation, also benefit since such sperm is associated with higher rates of chromosomally abnormal embryos. Finally, patients with repeated implantation failure despite good-quality embryos on morphology assessment are increasingly being offered PGT-A as a next diagnostic step by Delhi's reproductive specialists.

Understanding the sequence of events helps Delhi patients feel in control of what can otherwise seem like an opaque, highly technical process. Genetic testing integrates seamlessly into a standard IVF cycle with a few additional steps.

Step one is pre-cycle genetic counselling. Before ovarian stimulation begins, you and your partner meet with a genetic counsellor — often coordinated through HomeIVF's teleconsultation platform — to confirm the indication, choose the appropriate test type (PGT-A, PGT-M, or PGT-SR), and understand what results will and will not tell you. For PGT-M, the laboratory typically requires 4-6 weeks to design a customised genetic probe specific to your family's mutation, so early planning is essential.

Step two is controlled ovarian stimulation and egg retrieval — identical to a standard IVF cycle. Step three is fertilisation and blastocyst culture. Embryos are cultured in the laboratory until Day 5 or Day 6 when they reach blastocyst stage. Step four is embryo biopsy: trained embryologists remove 5-8 trophectoderm cells under a microscope using laser-assisted hatching. The biopsied embryos are then immediately vitrified (frozen) while results are awaited. Step five is genetic analysis in an accredited molecular genetics laboratory — Delhi has several NABL-accredited facilities equipped for NGS-based PGT. Results arrive in 10-14 working days. Step six is a frozen embryo transfer (FET) cycle, where only euploid or unaffected embryos are thawed and transferred.

Delhi's diverse and densely interconnected population means genetic counsellors at HomeIVF see a wide range of hereditary conditions. Awareness of regionally prevalent disorders can help couples seek testing proactively rather than reactively.

Beta-thalassaemia is one of the most commonly screened conditions in North India. India carries the world's highest burden of thalassaemia carriers, and communities across Delhi — including families from Punjab, Sindhi, and Gujarati backgrounds — have higher carrier rates. PGT-M allows carrier couples to have completely unaffected children without the need for prenatal diagnosis or difficult decisions mid-pregnancy.

Spinal muscular atrophy (SMA) has gained attention following the introduction of gene therapy in India, but prevention through PGD remains the most cost-effective approach. Fragile X syndrome, which is a leading inherited cause of intellectual disability, is another condition for which PGT-M probes are routinely designed in Delhi's genetics laboratories. Couples in Dwarka and other West Delhi communities with a prior affected child or a known family mutation are encouraged to seek genetic counselling at the earliest opportunity — ideally before they begin IVF stimulation — to allow adequate probe preparation time. Robertsonian and reciprocal chromosomal translocations, which may be detected when a patient in South Delhi presents with recurrent pregnancy loss, are addressed specifically through PGT-SR.

One of the most common questions the HomeIVF Medical Board receives from Delhi patients is: does genetic testing actually improve my chances of taking home a baby? The answer is nuanced and worth addressing honestly.

PGT-A does not increase the total number of euploid embryos you produce — it identifies which of your embryos are chromosomally normal. For women under 35 with no prior failures, the benefit of PGT-A is debated in international literature, as most embryos at this age are already euploid. However, for women over 37, the proportion of aneuploid embryos in a cohort can exceed 60-70%, making PGT-A highly valuable in selecting the right embryo on the first transfer attempt.

Frozen embryo transfer (FET) cycles using euploid embryos typically achieve clinical pregnancy rates of 60-70% per transfer in well-run programmes. IVF success rates in India typically range from 40-55% per cycle depending on age and cause, and PGT can meaningfully push outcomes toward the higher end of this range for appropriate patient groups. Importantly, PGT-A reduces the risk of a miscarriage after a positive pregnancy test — a deeply significant benefit for couples in Delhi who have already experienced pregnancy loss. Cumulative live birth rates across an entire IVF stimulation cycle (considering all biopsied and euploid embryos) are a more meaningful metric than per-transfer rates, and HomeIVF counsellors walk every patient through their specific expected outcomes based on age, ovarian reserve, and diagnosis.

Financial planning is a practical and valid concern for Delhi families considering genetic testing alongside IVF. The HomeIVF Medical Board believes in complete transparency around cost structures so that couples can make informed decisions.

PGT-A, which involves biopsy of all available blastocysts and NGS analysis, is typically priced as an add-on to the base IVF cycle. HomeIVF offers IVF packages starting from ₹1.5 lakh, with PGT-A costs structured as a per-embryo or per-cycle laboratory fee depending on the number of embryos biopsied. PGT-M involves additional probe design costs and a longer lead time — usually 4-6 weeks before the stimulation cycle begins — which patients in Rohini or South Delhi planning ahead should factor into their overall timeline.

A complete PGT-A cycle in Delhi, from stimulation start to embryo transfer, typically spans 6-10 weeks when a freeze-all strategy is used. PGT-M cycles may take 3-4 months from initial counselling to transfer due to probe design. Multiple embryos biopsied in a single retrieval cycle can be analysed together, improving the cost efficiency. HomeIVF's coordinators help patients in Delhi navigate CGHS or corporate insurance where applicable, as some policies do cover components of genetic testing when medically indicated. Financial counselling is available as part of the HomeIVF onboarding process.

For many couples in Delhi, the challenge is not simply finding a clinic that offers PGT — it is navigating the process without confusion, without wasted trips across the city, and without feeling lost in translation between highly technical medical information and everyday decision-making. This is precisely where HomeIVF changes the experience.

HomeIVF delivers senior-specialist care at home, meaning initial consultations, follow-up genetic counselling sessions, cycle monitoring scans, hormone injections, and post-transfer care can all be coordinated from your residence — whether you are in Dwarka in the west, Rohini in the north, or a South Delhi neighbourhood like Malviya Nagar or Greater Kailash. Our platform connects you to accredited genetics laboratories in Delhi for sample processing, while our medical coordinators manage logistics, appointment scheduling, and result communication.

For couples who are both working professionals — an increasingly common profile among Delhi's IVF patients — the ability to attend genetic counselling via video consultation in the evening, have monitoring blood draws conducted at home in the morning, and receive biopsy results digitally through the HomeIVF app removes the practical barriers that cause unnecessary delays. The HomeIVF Medical Board reviews each patient's PGT recommendation individually, ensuring that testing is advised only when it adds genuine clinical value and not as a routine commercial upsell.

Despite Delhi being one of India's most medically advanced cities, several real-world barriers prevent couples from accessing PGT/PGD in a timely and informed manner. Recognising these barriers is the first step to addressing them.

Awareness remains limited. Many couples presenting for IVF in Delhi — particularly those seeking treatment for the first time — are unaware that genetic testing exists or that their specific history (recurrent miscarriage, carrier status, advanced maternal age) makes them strong candidates. HomeIVF addresses this through structured pre-IVF assessments that flag genetic testing indications during the first consultation.

Cost anxiety is another significant barrier. Families in Delhi sometimes avoid asking about PGT because they assume it is prohibitively expensive. Transparent cost breakdowns and the option to include PGT in a structured package — rather than as a surprise add-on — make the conversation easier. Logistical friction — multiple clinic visits across Delhi traffic — is a barrier that HomeIVF directly solves through its at-home monitoring and teleconsultation model. Finally, stigma around genetic conditions in certain communities means that couples may delay PGD counselling even when they know a hereditary condition runs in the family. HomeIVF's counsellors approach these conversations with cultural sensitivity and confidentiality, providing a safe space for Delhi families to make informed reproductive decisions without judgment.